Cargando…
肺癌抗血管生成治疗:现状、进展与困惑
Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Adva...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051307/ https://www.ncbi.nlm.nih.gov/pubmed/35477192 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.16 |
Ejemplares similares
-
2017 ASCO及WCLC晚期非鳞NSCLC抗血管生成治疗进展
Publicado: (2018) -
晚期非小细胞肺癌抗血管生成药物的联合治疗模式
Publicado: (2021) -
抗血管生成药物联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌的研究进展
Publicado: (2022) -
小分子抗血管生成药物在非小细胞肺癌中的研究进展
Publicado: (2021) -
抗血管生成药物联合免疫检查点抑制剂治疗晚期非小细胞肺癌的研究进展
Publicado: (2021)